The most common neurological manifestations of antiphospholipid syndrome (APS) in all age-groups include stroke and transient ischemic attacks due to arterial thromboses and cerebral ischemia. Antiphospholipid antibodies may cause additional non-criteria neurological impairments through vascular, neuroinflammatory and direct neuronal effects. Anti-aggregant or anticoagulant therapies are indicated for APS-related ischemic strokes. Treatment regimens for asymptomatic antibody-positive patients and those with refractory or recurrent disease remain controversial. There is scant literature on the epidemiology and therapy of neurological APS manifestations in pediatric patients. Assessments of modifiable cardiovascular and inherited thrombophilia risk factors are essential in patients with APS. There may be a role for novel neuroimaging modalities in quantifying APS-related microstructural brain damage. The clinical utility of statins, antimalarials, angiotensinconverting enzyme inhibitors, and thrombin inhibitors warrant further research. Lupus (2010) 19, 406-411.
Potential mechanisms of neurological dysfunction in antiphospholipid syndrome
Antiphospholipid syndrome (APS) is a systemic autoimmune condition characterized by hypercoagulability, venous and/or arterial thromboses, and pregnancy morbidities. Neurological dysfunction may be related to a host of immune-mediated vascular, inflammatory, and direct neuronal effects ( Table 1) .
Antiphospholipid antibodies (aPL) may activate endothelial cells, platelets, and coagulation cascades and can exist in autoimmune disorders such as lupus. As in other vessels aPL induce a proinflammatory and procoagulant state in human brain microvascular endothelial cells. Local ischemia due to microvessel thrombi opens the blood-brain barrier (BBB). In lupus patients aPL-triggered leuco-adhesion and complement activation appear to increase BBB permeability. An influx of peripherally produced autoantibodies and cytokines could then lead to neurotoxicity. aPL binding of b 2glycoprotein I (b 2 GPI) may also impair normal inhibition of cerebrovascular atherogenesis. Interleukin-6 release is postulated to damage neuronal and astrocyte cells in APS patients as it does in neuropsychiatric lupus subjects. 1 In experimental models anti-b 2 GPI binds neuronal and astrocyte membranes and reduces cellular viability. aPL also depolarize synaptic rat brain extracts and may have similar effects in human nerve terminals. 2 aPL may induce neurotoxicity in cells through over-activation of glutamate receptors or may exert central nervous system (CNS) effects by directly reacting with brain lipids. 3 There are associations between aPL or lupus anticoagulants (LAC) and both platelet and endothelial cell-derived microparticles in ischemic brain diseases. 4 study methodologies. Some studies included only baseline aPL testing, did not include LAC testing, enrolled patients that would not currently meet APS classification criteria or did not assess aPL/ LAC at times of neurological events.
Case-control and prospective studies have shown robust associations between aPL or LAC and incident ischemic strokes in young adults. 5, 6 An extremely high odds ratio (OR) of 43.1 was reported for positive LAC tests and ischemic strokes in a study with a low LAC positivity rate in a control population (RATIO: Risk of Arterial Thrombosis in Relation to Oral Contraceptives). 6 Arterial thromboses most commonly occur in the cerebral circulation of APS patients and lead to ischemic stroke or transient ischemic attacks (TIA). Cerebral ischemia most often presents due to middle cerebral artery occlusion but may affect any cerebral arterial territory. 7 Stroke or TIA was the initial presentation in 29.9% of adults with APS in a large European cohort. 8 Stroke was an initial presentation in 18% of Latin American adult APS patients. 9 Stroke/TIA events were the most frequent recurrent events in the European cohort and led to a significant proportion of the cohort deaths. Thromboses were also the leading cause of mortality in the latter 5 years of a prospective multinational lupus cohort study. aPL-associated strokes accounted for 11.8% of these events in a predominantly young female cohort. 10 Cerebral manifestations (including infarcts) were also observed in 62% of the 250 patients in the European catastrophic antiphospholipid antibody syndrome (CAPS) registry. 11 Stroke was the cause of death in 13% of the 114 deaths in this CAPS registry.
The importance of modifiable vascular risk factors in the prevention of aPL-associated thromboses has been shown in adult lupus research studies. In Lupus in Minorities Nature Versus Nurture (LUMINA), a large multi-ethnic US lupus cohort, the mean number of traditional cardiovascular risk factors were higher in patients who developed thromboses. 12 Vascular events were independently predicted by aPL, smoking, C-reactive protein, and older age. The ORs of ischemic strokes in women (mean age of 39) with a positive LAC were significantly higher in smokers or users of oral contraceptives. 6 The presence of additional prothrombotic risk factors may enhance the clinical significance of aPL in individual patients. Asymptomatic aPL-positive patients should be counseled about traditional cardiovascular risk factors and join smoking cessation programs. Asymptomatic women with aPL positivity should be counseled about the additional hypercoagulable risks of oral contraception, smoking, and pregnancy.
In a few studies patients with lupus and isolated APS also showed associations between valvular heart disease and CNS manifestations. LAC positivity and valvular anomalies (i.e. vegetation, thickening, and regurgitation) were independent predictors of magnetic resonance imaging Antiphospholipid syndrome and the brain in pediatric and adult patients E Muscal and RL Brey (MRI)-proven cerebrovascular disease in lupus patients. 13 Chronic coagulopathy and immune complex deposition may cause valvular changes and embolization to cerebral vessels. Yet, the combined presence of positive aPL and a patent foramen ovale or thickened left-sided heart valves did not significantly increase subsequent cerebrovascular events in a cohort of patients with incident strokes (the Patent Foramen Ovale in the Cryptogenic Stroke Study (PICSS)-Antiphospholipid Antibodies and Stroke Study (APASS)). 14 Echocardiography (preferably trans-esophageal) may be warranted in patients with stroke and APS.
The role of aPL in pediatric strokes continues to be investigated. Transient and often non-pathogenic aPL are more prevalent in children and often seen after infections. 15 Yet, it is unclear whether primary pediatric APS is a rare entity due to less prominent childhood prothrombotic risk factors. Ischemic stroke was the initial manifestation of 26% of pediatric APS subjects in a multinational childhood APS registry (121 subjects; both primary and secondary APS). 16 Rates of stroke were higher in the primary APS subjects who were also younger at presentation. In this cohort, 7% of children presented with cerebral sinus venous thrombosis. A small pediatric study detected increased anticardiolipin (aCL) IgG antibodies in over 50% of patients with idiopathic cerebral ischemia. 17 Associations between positive LAC and cerebrovascular disease were reported in a Toronto cohort study of children with lupus. 18 Anti-b 2 GPI Abs were associated with cerebrovascular disease in children in a US pediatric lupus cohort. 19 Only aCL IgM Abs were associated with cerebrovascular disease in another US retrospective pediatric lupus cohort study. 20 
Non-criteria neurological events in pediatric and adult APS studies
The validity of associations between aPL and non-criteria manifestations remains controversial. Migraines (20.2%) and epilepsy (7%) were prevalent manifestations in the adult Euro-phospholipid cohort. 8 Chronic and recurrent small vessel ischemic events predispose patients to early-onset multi-infarct dementia. 7 Recurrent seizures are more prevalent in lupus patients with high titer aCL antibodies and may be associated with ischemic changes. APS manifestations such as cognitive dysfunction and demyelination may have both thrombotic and non-vascular mechanisms. Prospective studies associate persistent aPL positivity with cognitive impairments in lupus patients. Impairment is prominent in areas of attention, psychomotor speed and executive abilities, and is not associated with traditional lupus autoantibody titers. 21, 22 aPL-mediated damage to white matter (WM) tracts and basal ganglia structures may account for multiple sclerosis-like features and movement disorders in APS patients. 2 WM lesions were statistically more common in adults with high-titer aCL in a study of APS patients. 23 MRI lesions were visualized in subcortical and juxtacortical WM of the frontal and parietal lobes in a structure-function association study of adults with APS. The severity of these lesions predicted the number and type of cognitive domains impaired during neuropsychological evaluation. 24 Neuroimaging studies utilizing volumetric assessments, magnetization transfer imaging (MTI), and diffusion weighted imaging (DWI) reveal microstructural changes in primary APS patients even without previous CNS events. 25, 26 These 'novel' modalities appear to differentiate APS patients from those diagnosed with multiple sclerosis and who have more pronounced atrophy, higher lesion load, and abnormal diffusivity. 25 Migraines (7%), chorea (4%), and epilepsy (3%) were the most common non-thrombotic neurological manifestations in the only published pediatric APS registry. 16 Only the prevalence of anti-b 2 GPI Abs was found to be statistically higher in pediatric lupus patients with neuropsychiatric systemic lupus erythematosus in the Toronto cohort. 18 aPL (including anti-b 2 GPI) and LAC were not associated with non-thrombotic neurological manifestations in the two pediatric lupus cohorts described above. There have been no published neuroimaging studies of pediatric APS patients. No pediatric lupus structure-function association studies to date have assessed the role of aPL on cognition.
Current treatment recommendations for APS-mediated neurological manifestations: striving for evidence-based practice
Few studies have examined the efficacy of different therapies in the prevention of aPL-associated arterial ischemic strokes. The management of APS-mediated ischemic strokes is based on both retrospective and prospective studies with a predominance of venous thromboses. Two randomized controlled trials (RCT) powered to detect the superiority of high intensity warfarin regimens challenged treatment algorithms based on higher INR targets (from retrospective studies). Neither study showed a statistically significant difference in recurrent thrombosis rates when comparing moderate versus high intensity regimens. 27, 28 Yet, low rates of arterial thromboses and recurrence in these studies call into question their applicability to ischemic stroke.
Due to findings in the APASS study many clinicians treat incident aPL-related cerebral arterial events with aspirin or moderate intensity warfarin (INR 2-3 ). An important APASS caveat is that only 14% had moderate to highly positive aCL IgG or IgM titers, only 20% had positive LAC tests, and the published analysis was based on a single positive aPL determination. Analyses for 1770 patients in the APASS study receiving warfarin (INR 1.4-2.8) or aspirin (325 mg daily) were adjusted for age, sedentary lifestyle, and cardiac medical history. 29 There were no observed increases in death or thrombotic events associated with aPL positivity in either treatment group. Subgroup analyses for patients younger than 55 years and those with cryptogenic strokes revealed similar results. There were no differences in bleeding complications between aspirin and warfarin groups.
APS experts debate the implications of these prospective trials on cerebral arterial thrombosis treatment. APASS conclusions based on single antibody measurement may not generalize to APS patients with persistent and severe disease processes. Some experts believe that the recent RCT studies did not adequately investigate therapies in aPLassociated arterial disease. Arterial disease reflects potent antibody effects and often leads to increased morbidity and mortality. Indeed, strokes and TIAs were the most frequent recurrent thrombotic events in the Euro-phospholipid cohort, although a majority of patients were anticoagulated with an INR target of 2-3. 8 The Euro-phospholipid cohort investigators postulated that this moderate intensity warfarin regimen may only protect against venous events. Some researchers and clinicians still use high-intensity warfarin (INR 3-4) in patients with a history of lupus, recurrent thromboses or initial arterial event. Prospective studies of warfarin and aspirin in aPL-related arterial diseases are needed to settle these debates. There are no compelling data regarding treatments in the primary prevention of aPL-associated strokes in patients without a previous thrombosis. Asymptomatic, persistently aPL-positive individuals did not benefit from low-dose aspirin for primary thrombosis prophylaxis when compared with those on placebo in a recent study. 30 There is no compelling evidence regarding optimal treatment of patients with recurrent thromboses while anticoagulated. A subtherapeutic INR at the time of thrombosis may represent inadequate anticoagulation and not treatment failure. Thrombo-occlusive events despite proper INR ranges may respond to increased INR targets (>3), or switching to heparin products (lowmolecular or unfractionated), or combination therapy with aspirin. Patients with systemic inflammation during a lupus flare or those with diffuse micro-angiopathy (CAPS) may require intravenous immunoglobulin, plasma exchange and/or corticosteroid therapy. 11 There are no expert opinions or trials that have examined warfarin, aspirin or heparin performance in childhood APS. Although pediatric practices often approximate adult care only 40% of children with arterial thrombosis in the pediatric APS registry received anticoagulation (with or without aspirin). Indeed, five of eight children with recurrent arterial thromboses in this registry were not anticoagulated after their initial arterial event.
Future directions in neuro-APS
Caring for APS patients with neurological manifestations remains a complex endeavor that requires individualized patient risk assessment. Clinicians must recognize the limits of available Understanding associations between aPL and non-stroke-related neurological manifestations warrant further research support. Neuroimaging modalities that assess microstructural WM damage (such as DWI or diffusion tensor imaging, DTI), or perfusion changes (through arterial spin labeling MRI), may allow for identification of early CNS damage in APS patients. Future APS clinical trials may also address novel vascular and immune targets. Statins are attractive agents in the treatment of APS patients as they block aPL-induced endothelial cell activation and inhibit small GTP-binding protein-mediated intracellular signaling. Downstream endothelial and platelet effects of this inhibition include increased nitric oxide synthase and fibrinolytic activity. Statin therapy improves hyperlipidemia and may inhibit b 2 GPI antibody-induced monocyte tissue factor (TF) over-expression. Angiotensin-converting enzyme and adenosine uptake inhibitors may have similar effects on TF expression. Hydroxychloroquine, an antimalarial agent long utilized in lupus, appears to have both anti-aggregant and anti-inflammatory effects. Mechanisms for this drug's action in APS include reduction of platelet activation, and modulation of B-and T-cell receptor signaling. Newer oral anticoagulants, such as thrombin inhibitors, may have safer profiles and require less frequent monitoring.
